PROGRAMME



Scandinavian College of NeuroPsychopharmacology

SCNP

http://scnp.org

61st Annual Meeting of the Scandinavian College of NeuroPsychopharmacology

Stockholm – 7-9 June 2023

Welcome to SCNP 2023

Dear SCNP 2023 participant,

WELCOME

Welcome to the 61^{st} annual meeting of the SCNP. We have attempted to create a programme with broad appeal.

WE WANT YOUR EVALUATION

As we can always improve our efforts, we kindly ask all participants to fill in the anonymous evaluation form online during the meeting. You can also make suggestions for future meetings, as well as other general comments.

POSTER SESSION

During the poster session, the scientific committee will evaluate the best posters exhibited. The best clinical and best preclinical poster will be awarded each \in 500 during the dinner.

YOUNG SCIENTISTS' SYMPOSIUM

One of the main traditions in the history of SCNP is the young scientists' symposium (see page 6), held in the afternoon on Thursday, 8 June.

Six young researchers will present their work in a prestigious competition of the SCNP Young Scientist Award 2023, and €2000.

The SCNP board

Board members

2023

President: Professor Sophie Erhardt Stockholm (SE)

Vice President: Professor Bo Söderpalm Gothenburg (SE)

Past President:

Professor Gregers Wegener Aarhus (DK)

Henry Karlsson, MD, PhD Turku (FI)

Ingrid Dieset, MD, PhD Oslo (NO)

Professor Halldora Jonsdottir Reykjavik (IS)

Carl Björkholm, PhD Stockholm (SE)

Meeting Exhibitors:













anssen PHARMACEUTICAL COMPANIES OF Johnson + Johnson

Congress

Programme

PRE-MEETING EVENT

WEDNESDAY, 7 JUNE 2023

14.00-17.00 SCNP EDUCATIONAL WORKSHOP

MECHANISM OF ACTION OF ANTIDEPRESSANTS

Moderators Gregers Wegener, Aarhus University, Denmark, Carl Björkholm, PhD, Janssen Pharmaceuticals, Sweden

14.00-14.05: Welcome

14.05-15.25: **TREATMENT RESISTANT DEPRESSION REVISITED Angelos Halaris**, Loyola University Chicago, USA

15.25-15.45: BREAK

15.45-16.55: **EXPLORING CANNABINOIDS FOR DEPRESSION: UNVEILING THE MYTHS, EMBRACING THE PROMISES Samia Joca**, Aarhus University, Denmark.

16.55-17.00: Round off and evaluation

THURSDAY, 8 JUNE 2023

08.30- REGISTRATION OPENS (COFFEE)

09.00-09.30 SCNP GENERAL ASSEMBLY (MEMBERS ONLY)

09.30-09.45 SCNP PRESIDENT'S WELCOME TO 61st ANNUAL MEETING

Sophie Erhardt, Professor, Karolinska Institutet, Sweden

09.45-10.30 OPENING LECTURE

SCNP 2023 Opening Lecture

Moderator: Carl Björkholm, PhD, Janssen Pharmaceuticals, Sweden

Future therapies for Alzheimer's disease

Lars Lannfelt, Professor, Uppsala University, Sweden

10.30 COFFEE BREAK AND POSTER VIEWING

10.50-12.30 GENETICS AND IMMUNOLOGICAL

ASPECTS IN PSYCHIATRY

Moderator: Sophie Erhardt (Stockholm, Sweden)

Diagnosis and treatment of maladaptive immunological responses presenting with psychiatric phenotypes

Janet Cunningham, Assoc- Prof, Uppsala University, Sweden

Treatment with minocycline and schizophrenia Carl Sellgren. MD, PhD, Karolinska Institutet, Sweden

Congress

Programme

Shared genetic risk across psychiatric and neurological disorders

Olav Bjerkehagen Smeland, MD, PhD, University of Oslo, Norway

Understanding the genetics of psychiatric disorders in the era of GWAS

Sarah Bergen, PhD, Karolinska Institutet, Sweden

Lithium - pharmacokinetics, genetics and nanofluidics Martin Schalling, Professor, Karolinska Institutet, Sweden

12.30-13.30 LUNCH and Poster viewing

13.30-15.00 SCNP YOUNG SCIENTIST SYMPOSIUM

Moderator: Gregers Wegener (Aarhus, Denmark)

Risk factors for developing disorder and impulsecontrol disorders under dopaminergic medication

Mirjan Wolfschlag

Faculty of Medicine, Dept of Clinical Sciences Lund, Lund University, Psychiatry, Lund, Sweden, & Malmö-Trelleborg Addiction Center, Competence Center Addiction, Region Skåne, Malmö, Sweden

Initiation of antidepressant treatment and the risk of manic episodes in children and adolescents with unipolar depression

Suvi Virtanen, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden

Quasi-tenacious depression (QTD) as an alternative framework to treatment-resistant depression (TRD)

Shokouh Arjmand

Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Cardiovascular proteins are elevated in first-episode psychosis patiens compared to healty controls

Anna Kristina Malmqvist-Bahrami Karolinska institutet, Sweden

Accumbal Cholinergic signaling regulates ethanol intake in the rat

Anna Loftén Addiction Biology Unit, Institution of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Sweden & Beroendekliniken, Shalgrenska University Hospital, Gothenburg, Sweden

Kynurenic acid promotes activity-dependent synaptic pruning and associates with genetic risk variance for schizophrenia

Funda Orhan Karolinska Institutet, Sweden

15.00-15.30 COFFEE BREAK AND POSTER VIEWING

15.30-16.30 Treatment of depressive disorders

Moderator: Ingrid Dieset, MD, PhD, Oslo University, Norway

Management of treatment-resistant depression: old ideas (& new)

Elias Eriksson, Professor, Gothenburg University, Sweden

Real-World effectiveness of pharmacotherapies in psychotic depression

Heidi Taipale, PhD, Karolinska Institutet, Sweden

16.30 POSTER VIEWING AND REFRESHMENTS

Congress

Programme

Social Programme SCNP 2023


Thursday 8 June

18.30 Buses leave outside of Biomedicum, KI

19.00 Guided tours at the National Museum https://www.nationalmuseum.se/

20.00 SCNP 2023 Dinner

Nationalmuseum Södra Blasieholmshamnen 2 Stockholm



FRIDAY, 9 JUNE 2023

08.30-09.10 SCNP LECTURE

Moderator: Bo Söderpalm, Professor, Gothenburg University, Sweden

Cannabis - The Good, The Bad and The Ugly in Relation to Psychiatric Disorders

Yasmin Hurd, Professor, Icahn School of Medicine at Mount Sinai, USA

09.10-09.55 IN MEMORIAN OF TORGNY H. SVENSSON

Moderator: Sophie Erhardt, Professor, Karolinska Institutet, Sweden

Professor Torgny H. Svensson 1945-2020

Göran Engberg, Professor, Karolinska Institutet, Sweden

The Torgny H. Svensson Award Lecture

Rethinking the mechanism of antidepressants (on TRKB)

Plinio Casarotto, PhD

09.55-10.20 Honorary member lecture

Psychedelics in depression - opportunities and challenges

Prof. Ole Andreassen, Professor Oslo University, Norway

10.20-10.45 COFFEE BREAK AND POSTER VIEWING

10.45-12.15 UPDATE ON NEW DRUGS

Moderator: Henry Karlsson, Assoc. Prof. University of Turku, Finland

Targeting Brain Kynurenic Acid for Cognitive Improvement

Robert Schwarcz, Professor, University of Maryland School of Medicine, USA

Ulotaront: A Novel TAAR1 Agonist in Development for the Treatment of Schizophrenia

Nicholas DeMartinis, MD, VP Head of Global Clinical Research Psychiatry, Sunovion Pharmaceuticals Inc.

Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder

Susanne Bejerot, Professor, Örebro University, Sweden

12.15-13.15 LUNCH AND POSTER VIEWING

13.15-14.00 SCNP LECTURE

Moderator: Bo Söderpalm, Professor, Gothenburg University, Sweden

Treatment Strategies for ADHD and Co-occurring Substance Use/Use Disorders

Frances Levin, Professor, Columbia University, USA

14.00-14.20 COFFEE BREAK AND POSTER VIEWING

14.20-16.00 ADDICTION, SUICIDE AND ADHD

Moderator: Carl Björkholm, PhD, Janssen Pharmaceuticals, Sweden

Suicide prevention - how to turn the tide?

Merete Nordentoft, Professor, University of Copenhagen, Denmark

Neuromodulation of subjective experience

Siri Leknes, Professor, University of Oslo, Norway

Role of Cognition in Alcohol Use Disorders

Nitya Jayaram Lindström, PhD, Karolinska Institutet, Sweden

Gut-brain axis and addictive disorders

Elisabet Jerlhag Holm, Professor, Gothenburg University, Sweden

Prevalence and pattern of intravenous use of methylphenidate in Iceland

Gudrun Bjarnadottir, PhD, Landspitali University Hospital, Iceland

16.00 CONCLUSION OF THE MEETING

Sophie Erhardt & Bo Söderpalm

Join SCNP

ABOUT SCNP

SCNP (Scandinavian College of Neuropsychopharmacology) is the leading psychopharmacology organisation in the Nordic countries, Sweden, Norway, Denmark, Iceland and Finland.

Its mission is to promote research and education in neuropsychopharmacology. It also provides advice on all aspects of neuro-psychiatric drugs. Through these activities, SCNP seeks to advance research thus leading to improved patient care.

The SCNP journal, 'Acta Neuropsychiatrica' is becoming an essential journal and grows in importance.

SCNP welcomes membership applications from all who are dedicated to the highest quality research in neuropsychopharmacology.

Benefits of Membership

- Being part of the leading Nordic organisation focused on neuropsychopharmacology.
- Your own personal subscription including on-line access to 'Acta Neuropsychiatrica', as well as a heavily discounted delegate fee for all meetings organised by SCNP.
- Access to the members-only area on the website, from where selected presentations from the annual meetings can be streamed
- Regular SCNP member letters.


The regular annual membership fee is very low, in 2023, only DKK 400. We invite you to send in your application...! https://scnp.org/become-member



Acta

Neuropsychiatrica 'The journal of SCNP'

Acta Neuropsychiatrica is an international journal that publishes translational high-quality research papers in neuropharmacology, neuropsychiatry and neuroscience.



The journal provides a forum for original basic and clinical research from disciplines and research areas relevant to the pathophysiology, neurobiology, and treatment of neuropsychiatric disorders.

Acta Neuropsychiatrica provides its readership with the latest perspectives from current and emerging fields of psychiatry, neurology, pharmacology, genetics and neuroimaging. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques/strategies. Emphasis will be given to translational original research that is of wide interest and clearly advances the field.

Acta Neuropsychiatrica welcomes Full-length Original Research Articles, Short Communications, Perspectives, as well as Review Articles. Debate is encouraged in the form of Letters to the Editor. All articles published in Acta Neuropsychiatrica undergo peer review.

Acta Neuropsychiatrica is published bi-monthly by Cambridge University Press on behalf of SCNP, and freely available to all members of SCNP.



Acknowledgements

At the 61st Annual Meeting of the SCNP, the Board wishes to acknowledge the unrestricted grants from **Agnthos, Scanbur, Medice, Sunovion, Mindmore and Takeda** enabling SCNP to invite speakers of highest international standards to our meeting.

In particular, the Board of the SCNP wish to acknowledge that **Acta Neuropsychiatrica** has made it possible for the SCNP to invite young scientists to participate in a competition for an oral presentation in the Young Scientists Symposium. The winner of the competition will receive 'The SCNP Award to Young Scientists'.

This initiative has developed into a most valuable tradition of the SCNP Annual meetings and has added very much to stimulating young scientists in their performance when participating in scientific meetings.

We would also like to acknowledge the Karolinska Institutet <i>for supporting our meeting with the meeting facilities.

Without these sponsorships, we would not have reached the high standard of the meeting.

On behalf of the Board of the SCNP

Yours sincerely

Sophie Erhardt, President

